Literature DB >> 11162316

Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors.

K Xu1, H Ma, T J McCown, I M Verma, T Kafri.   

Abstract

To facilitate the generation of SIN lentivirus vector-producer cell lines, we have developed a novel conditional SIN (cSIN) lentivirus vector, which retains its SIN properties in normal target cells yet can be produced at high titers from tetracycline-regulated packaging cell lines. The design of the cSIN vector is based on replacing the vector U3 transcription regulatory elements with the Tet-responsive element, which allows vector production exclusively in cells expressing the synthetic Tet-regulated transactivator (tTA). In contrast minimal vector production ( approximately 200 IU/ml) is obtained in target cells that do not express the tTA, even in the presence of all HIV-1 proteins. Following transduction of the Tet-regulated SODk1 lentivirus vector-packaging cell line with the cSIN vector, high titers of cSIN recombinant vector (>10(6) IU/ml) could be generated, which efficiently transduced terminally differentiated neurons in normal rat brain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11162316     DOI: 10.1006/mthe.2000.0238

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  48 in total

Review 1.  Gene therapy for glioblastoma: future perspective for delivery systems and molecular targets.

Authors:  A Shir; A Levitzki
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

2.  Notable reduction in illegitimate integration mediated by a PPT-deleted, nonintegrating lentiviral vector.

Authors:  Boris Kantor; Matthew Bayer; Hong Ma; Jude Samulski; Chengwen Li; Thomas McCown; Tal Kafri
Journal:  Mol Ther       Date:  2010-12-14       Impact factor: 11.454

3.  Mobilization and mechanism of transcription of integrated self-inactivating lentiviral vectors.

Authors:  Hideki Hanawa; Derek A Persons; Arthur W Nienhuis
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 4.  Altering the tropism of lentiviral vectors through pseudotyping.

Authors:  James Cronin; Xian-Yang Zhang; Jakob Reiser
Journal:  Curr Gene Ther       Date:  2005-08       Impact factor: 4.391

5.  Isolation, characterization, and genetic complementation of a cellular mutant resistant to retroviral infection.

Authors:  Sumit Agarwal; Josephine Harada; Jeffrey Schreifels; Patrycja Lech; Bryan Nikolai; Tomoyuki Yamaguchi; Sumit K Chanda; Nikunj V Somia
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-16       Impact factor: 11.205

6.  RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.

Authors:  Anna Stornaiuolo; Bianca Maria Piovani; Sergio Bossi; Eleonora Zucchelli; Stefano Corna; Francesca Salvatori; Fulvio Mavilio; Claudio Bordignon; Gian Paolo Rizzardi; Chiara Bovolenta
Journal:  Hum Gene Ther Methods       Date:  2013-08-03       Impact factor: 2.396

Review 7.  Recent advances in lentiviral vector development and applications.

Authors:  Janka Mátrai; Marinee K L Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

8.  Antibody Binding to CD4 Induces Rac GTPase Activation and Alters T Cell Migration.

Authors:  Y Maurice Morillon; Elizabeth Chase Lessey-Morillon; Matthew Clark; Rui Zhang; Bo Wang; Keith Burridge; Roland Tisch
Journal:  J Immunol       Date:  2016-09-30       Impact factor: 5.422

Review 9.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

10.  Design and in vivo characterization of self-inactivating human and non-human lentiviral expression vectors engineered for streptogramin-adjustable transgene expression.

Authors:  Barbara Mitta; Cornelia C Weber; Markus Rimann; Martin Fussenegger
Journal:  Nucleic Acids Res       Date:  2004-07-16       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.